| Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The lancet 380 (9856), 1829-1839, 2012 | 1079 | 2012 |
| Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012 | 1078 | 2012 |
| Alemtuzumab vs. interferon beta-1a in early multiple sclerosis AJ Coles, DA Compston, KW Selmaj, SL Lake, S Moran, DH Margolin, ... N Engl J Med 359 (17), 1786-1801, 2008 | 966 | 2008 |
| McAlpine's multiple sclerosis D McAlpine, A Compston Elsevier Health Sciences, 2005 | 787 | 2005 |
| Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis AJ Coles, MG Wing, P Molyneux, A Paolillo, CM Davie, G Hale, D Miller, ... Annals of Neurology: Official Journal of the American Neurological …, 1999 | 585 | 1999 |
| The window of therapeutic opportunity in multiple sclerosis AJ Coles, A Cox, E Le Page, J Jones, SA Trip, J Deans, S Seaman, ... Journal of neurology 253 (1), 98-108, 2006 | 555 | 2006 |
| Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis AJ Coles, M Wing, S Smith, F Coraddu, S Greer, C Taylor, A Weetman, ... The Lancet 354 (9191), 1691-1695, 1999 | 512 | 1999 |
| Disease-relevant autoantibodies in first episode schizophrenia MS Zandi, SR Irani, B Lang, P Waters, PB Jones, P McKenna, AJ Coles, ... Journal of neurology 258 (4), 686-688, 2011 | 344 | 2011 |
| IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H) JL Jones, CL Phuah, AL Cox, SA Thompson, M Ban, J Shawcross, ... The Journal of clinical investigation 119 (7), 2052-2061, 2009 | 319 | 2009 |
| Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis AL Cox, SAJ Thompson, JL Jones, VH Robertson, G Hale, H Waldmann, ... European journal of immunology 35 (11), 3332-3342, 2005 | 306 | 2005 |
| Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis T Moreau, A Coles, M Wing, J Isaacs, G Hale, H Waldmann, A Compston Brain 119 (1), 225-237, 1996 | 294 | 1996 |
| Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial AJ Coles, E Fox, A Vladic, SK Gazda, V Brinar, KW Selmaj, A Skoromets, ... Neurology 78 (14), 1069-1078, 2012 | 286 | 2012 |
| Mutations in the selenocysteine insertion sequence–binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans E Schoenmakers, M Agostini, C Mitchell, N Schoenmakers, L Papp, ... The Journal of clinical investigation 120 (12), 4220-4235, 2010 | 277 | 2010 |
| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 262 | 2019 |
| Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H A Paolillo, AJ Coles, PD Molyneux, M Gawne–Cain, D MacManus, ... Neurology 53 (4), 751-751, 1999 | 249 | 1999 |
| Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy O Tuohy, L Costelloe, G Hill-Cawthorne, I Bjornson, K Harding, ... Journal of Neurology, Neurosurgery & Psychiatry 86 (2), 208-215, 2015 | 234 | 2015 |
| Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort M Cossburn, AA Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, ... Neurology 77 (6), 573-579, 2011 | 232 | 2011 |
| B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis SAJ Thompson, JL Jones, AL Cox, DAS Compston, AJ Coles Journal of clinical immunology 30 (1), 99-105, 2010 | 232 | 2010 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 227 | 2017 |
| Neurological implications of COVID-19 infections EJ Needham, SHY Chou, AJ Coles, DK Menon Neurocritical care 32 (3), 667-671, 2020 | 199 | 2020 |
Jeffrey A CohenCleveland ClinicVerified email at ccf.org
